|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Crispen PL, Boorjian SA, Lohse CM,
Leibovich BC and Kwon ED: Predicting disease progression after
nephrectomy for localized renal cell carcinoma: the utility of
prognostic models and molecular biomarkers. Cancer. 113:450–460.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Zisman A, Pantuck AJ, Wieder J, et al:
Risk group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Klatte T, Seligson DB, Leppert JT, et al:
The chemokine receptor CXCR3 is an independent prognostic factor in
patients with localized clear cell renal cell carcinoma. J Urol.
179:61–66. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Frank I, Blute ML, Cheville JC, Lohse CM,
Weaver AL and Zincke H: An outcome prediction model for patients
with clear cell renal cell carcinoma treated with radical
nephrectomy based on tumor stage, size, grade and necrosis: the
SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Patard JJ, Kim HL, Lam JS, et al: Use of
the University of California Los Angeles integrated staging system
to predict survival in renal cell carcinoma: an international
multicenter study. J Clin Oncol. 22:3316–3322. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Zisman A, Pantuck AJ, Dorey F, et al:
Improved prognostication of renal cell carcinoma using an
integrated staging system. J Clin Oncol. 19:1649–1657.
2001.PubMed/NCBI
|
|
9.
|
Lam JS, Klatte T, Kim HL, et al:
Prognostic factors and selection for clinical studies of patients
with kidney cancer. Crit Rev Oncol Hematol. 65:235–262. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar
|
|
11.
|
Marhaba R and Zoller M: CD44 in cancer
progression: adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Naor D, Sionov RV and Ish-Shalom D: CD44:
structure, function, and association with the malignant process.
Adv Cancer Res. 71:241–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Tawfik OW, Kramer B, Shideler B, Danley M,
Kimler BF and Holzbeierlein J: Prognostic significance of CD44,
platelet-derived growth factor receptor alpha, and cyclooxygenase 2
expression in renal cell carcinoma. Arch Pathol Lab Med.
131:261–267. 2007.PubMed/NCBI
|
|
14.
|
Liao HX, Lee DM, Levesque MC and Haynes
BF: N-terminal and central regions of the human CD44 extracellular
domain participate in cell surface hyaluronan binding. J Immunol.
155:3938–3945. 1995.PubMed/NCBI
|
|
15.
|
Lim SD, Young AN, Paner GP and Amin MB:
Prognostic role of CD44 cell adhesion molecule expression in
primary and metastatic renal cell carcinoma: a clinicopathologic
study of 125 cases. Virchows Arch. 452:49–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Bamias A, Chorti M, Deliveliotis C, et al:
Prognostic significance of CA 125, CD44, and epithelial membrane
antigen in renal cell carcinoma. Urology. 62:368–373. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Wu ST, Sun GH, Hsieh DS, Chen A, Chen HI,
Chang SY and Yu D: Correlation of CD44v5 expression with
invasiveness and prognosis in renal cell carcinoma. J Formos Med
Assoc. 102:229–233. 2003.PubMed/NCBI
|
|
18.
|
Paradis V, Ferlicot S, Ghannam E, et al:
CD44 is an independent prognostic factor in conventional renal cell
carcinomas. J Urol. 16:1984–1987. 1999. View Article : Google Scholar
|
|
19.
|
Rioux-Leclercq N, Epstein JI, Bansard JY,
et al: Clinical significance of cell proliferation, microvessel
density, and CD44 adhesion molecule expression in renal cell
carcinoma. Hum Pathol. 32:1209–1215. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lucin K, Matusan K, Dordević G and Stipić
D: Prognostic significance of CD44 molecule in renal cell
carcinoma. Croat Med J. 45:703–708. 2004.PubMed/NCBI
|
|
21.
|
Gilcrease MZ, Guzman-Paz M, Niehans G,
Cherwitz D, McCarthy JB and Albores-Saavedra J: Correlation of
CD44S expression in renal clear cell carcinomas with subsequent
tumor progression or recurrence. Cancer. 86:2320–2326. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Heider KH, Ratschek M, Zatloukal K and
Adolf GR: Expression of CD44 isoforms in human renal cell
carcinomas. Virchows Arch. 428:267–273. 1996.PubMed/NCBI
|
|
23.
|
Matusan K, Dordevic G, Mozetic V and Lucin
K: Expression of osteopontin and CD44 molecule in papillary renal
cell tumors. Pathol Oncol Res. 11:108–113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lee SM, Lee KE, Chang HJ, et al:
Prognostic significance of CD44s expression in biliary tract
cancers. Ann Surg Oncol. 15:1155–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zeilstra J, Joosten SP, Dokter M, Verwiel
E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer
stem cell marker CD44 in Apc(Min/+) mice attenuates
intestinal tumorigenesis. Cancer Res. 68:3655–3661. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and
Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic
stem cells. Nat Med. 12:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Krause DS, Lazarides K, von Andrian UH and
van Etten RA: Requirement for CD44 in homing and engraftment of
BCR-ABL-expressing leukemic stem cells. Nat Med. 12:1175–1180.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Huh JW, Kim HR, Kim YJ, Lee JH, Park YS,
Cho SH and Joo JK: Expression of standard CD44 in human colorectal
carcinoma: association with prognosis. Pathol Int. 59:241–246.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Terpe HJ, Störkel S, Zimmer U, Anquez V,
Fischer C, Pantel K and Günthert U: Expression of CD44 isoforms in
renal cell tumors. Positive correlation to tumor differentiation.
Am J Pathol. 148:453–463. 1996.PubMed/NCBI
|
|
31.
|
Zolota V, Tsamandas AC, Melachrinou M,
Batistatou A and Scopa C: Expression of CD44 protein in renal cell
carcinomas: association with p53 expression. Urol Oncol. 7:13–17.
2002. View Article : Google Scholar : PubMed/NCBI
|
